Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Bonsignori, M.
  • Hwang, K. K.
  • Chen, X.
  • Tsao, C. Y.
  • Morris, L.
  • Gray, E.
  • Marshall, D. J.
  • Crump, J. A.
  • Kapiga, S. H.
  • Sam, N. E.
  • Sinangil, F.
  • Pancera, M.
  • Yongping, Y.
  • Zhang, B.
  • Zhu, Jiang
  • Kwong, P. D.
  • O'Dell, S.
  • Mascola, J. R.
  • Wu, L.
  • Nabel, G. J.
  • Phogat, S.
  • Seaman, M. S.
  • Whitesides, J. F.
  • Moody, M. A.
  • Kelsoe, G.
  • Yang, X.
  • Sodroski, J.
  • Shaw, G. M.
  • Montefiori, D. C.
  • Kepler, T. B.
  • Tomaras, G. D.
  • Alam, S. M.
  • Liao, H. X.
  • Haynes, B. F.

publication date

  • October 2011

journal

  • Journal of Virology  Journal

abstract

  • V2/V3 conformational epitope antibodies that broadly neutralize HIV-1 (PG9 and PG16) have been recently described. Since an elicitation of previously known broadly neutralizing antibodies has proven elusive, the induction of antibodies with such specificity is an important goal for HIV-1 vaccine development. A critical question is which immunogens and vaccine formulations might be used to trigger and drive the development of memory B cell precursors with V2/V3 conformational epitope specificity. In this paper we identified a clonal lineage of four V2/V3 conformational epitope broadly neutralizing antibodies (CH01 to CH04) from an African HIV-1-infected broad neutralizer and inferred their common reverted unmutated ancestor (RUA) antibodies. While conformational epitope antibodies rarely bind recombinant Env monomers, a screen of 32 recombinant envelopes for binding to the CH01 to CH04 antibodies showed monoclonal antibody (MAb) binding to the E.A244 gp120 Env and to chronic Env AE.CM243; MAbs CH01 and CH02 also bound to transmitted/founder Env B.9021. CH01 to CH04 neutralized 38% to 49% of a panel of 91 HIV-1 tier 2 pseudoviruses, while the RUAs neutralized only 16% of HIV-1 isolates. Although the reverted unmutated ancestors showed restricted neutralizing activity, they retained the ability to bind to the E.A244 gp120 HIV-1 envelope with an affinity predicted to trigger B cell development. Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies.

subject areas

  • Antibodies, Neutralizing
  • Epitopes
  • Female
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV-1
  • Humans
  • Neutralization Tests
  • Protein Binding
  • Surface Plasmon Resonance
scroll to property group menus

Identity

PubMed Central ID

  • PMC3196428

International Standard Serial Number (ISSN)

  • 0022-538X

Digital Object Identifier (DOI)

  • 10.1128/jvi.05045-11

PubMed ID

  • 21795340
scroll to property group menus

Additional Document Info

start page

  • 9998

end page

  • 10009

volume

  • 85

issue

  • 19

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support